SG55071A1 - Antipsychotic method - Google Patents

Antipsychotic method

Info

Publication number
SG55071A1
SG55071A1 SG1996004738A SG1996004738A SG55071A1 SG 55071 A1 SG55071 A1 SG 55071A1 SG 1996004738 A SG1996004738 A SG 1996004738A SG 1996004738 A SG1996004738 A SG 1996004738A SG 55071 A1 SG55071 A1 SG 55071A1
Authority
SG
Singapore
Prior art keywords
mammal
antipsychotic method
antipsychotic
schizophrenia
sulphur
Prior art date
Application number
SG1996004738A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SG55071A1 publication Critical patent/SG55071A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG1996004738A 1993-08-19 1994-08-15 Antipsychotic method SG55071A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19

Publications (1)

Publication Number Publication Date
SG55071A1 true SG55071A1 (en) 1998-12-21

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004738A SG55071A1 (en) 1993-08-19 1994-08-15 Antipsychotic method

Country Status (23)

Country Link
EP (1) EP0734259B1 (fi)
JP (1) JP3126736B2 (fi)
KR (1) KR100360575B1 (fi)
CN (1) CN1087936C (fi)
AT (1) ATE218864T1 (fi)
AU (1) AU701292B2 (fi)
CA (1) CA2169839C (fi)
CZ (1) CZ285030B6 (fi)
DE (1) DE69430816T2 (fi)
DK (1) DK0734259T3 (fi)
ES (1) ES2177581T3 (fi)
FI (2) FI960747A (fi)
HU (1) HU221729B1 (fi)
IL (1) IL110708A (fi)
NO (1) NO312706B1 (fi)
NZ (2) NZ271311A (fi)
PT (1) PT734259E (fi)
RU (1) RU2191580C2 (fi)
SG (1) SG55071A1 (fi)
TW (1) TW442284B (fi)
UA (1) UA63876C2 (fi)
WO (1) WO1995005174A1 (fi)
ZA (1) ZA946324B (fi)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5929247A (en) * 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
IL115811A0 (en) * 1994-10-31 1996-01-19 Lilly Co Eli Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
DK0821955T3 (da) * 1996-08-01 2002-03-18 Lilly Co Eli Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
AU7639598A (en) 1997-05-29 1998-12-30 H. Lundbeck A/S Treatment of schizophrenia and psychosis
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
EP3646870A1 (en) 2009-07-22 2020-05-06 Puretech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
NO312706B1 (no) 2002-06-24
HU9600364D0 (en) 1996-04-29
KR960703592A (ko) 1996-08-31
RU2191580C2 (ru) 2002-10-27
CN1087936C (zh) 2002-07-24
CA2169839C (en) 2002-06-11
ZA946324B (en) 1996-02-19
DE69430816T2 (de) 2002-12-19
AU7490294A (en) 1995-03-14
HU221729B1 (hu) 2002-12-28
DK0734259T3 (da) 2002-09-30
HUT75111A (en) 1997-04-28
FI960747A (fi) 1996-04-17
CN1133008A (zh) 1996-10-09
WO1995005174A1 (en) 1995-02-23
ATE218864T1 (de) 2002-06-15
PT734259E (pt) 2002-11-29
CA2169839A1 (en) 1995-02-23
JP3126736B2 (ja) 2001-01-22
NZ336597A (en) 2001-02-23
UA63876C2 (en) 2004-02-16
KR100360575B1 (ko) 2003-03-10
DE69430816D1 (de) 2002-07-18
IL110708A (en) 1998-12-06
NZ271311A (en) 1999-09-29
TW442284B (en) 2001-06-23
EP0734259B1 (en) 2002-06-12
IL110708A0 (en) 1994-11-11
FI20050461A (fi) 2005-04-29
NO960619D0 (no) 1996-02-16
CZ285030B6 (cs) 1999-05-12
FI960747A0 (fi) 1996-02-19
CZ42696A3 (en) 1996-11-13
EP0734259A1 (en) 1996-10-02
JPH09501658A (ja) 1997-02-18
NO960619L (no) 1996-04-18
ES2177581T3 (es) 2002-12-16
AU701292B2 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
FI20050461A (fi) Antipsykoottinen käyttö
EP0604641A4 (en) COMPOSITION CONTAINING AMINO DERIVATIVES OR RELATED TO BENZOIC ACID AMINES AND USES THEREOF, INCLUDING IN THE TREATMENT OF INFLAMMATORY DISEASES.
ES8706149A1 (es) Procedimiento para preparar 4h-1-benzopiran-4-onas
HUT73854A (en) Antipsychotic pharmaceutical compositions containing azabicyclo-thiadiazolo- or azabicyclo-oxadiazolo-derivatives
MX9803901A (es) Compuestos de di-terbutilfenol que contienen azufre utiles como agentes anti-inflamatorios.
ZA908460B (en) Benzocycloalkylaminopyridinamines and related compounds,a process and intermediates for their preparation and their use as medicaments
GR852867B (fi)
NO20003481L (no) FremgangsmÕte for behandling av COPD
ZA9410287B (en) N-oxides of 4-arylpiperazines and 4-arylpiperidines
AU653311B2 (en) Benzo(B)thiophen-3-yl-piperazines, as anti-psychotic agents
AU4610689A (en) Pyridine-3-peroxycarboxylic acid monopersulfate
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders